Search | Clinical Trials Finder

Conditions: Gingival Inflammation
Interventions: Flossing technique; Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Blood Loss, Surgical, Postpartum Hemorrhage, Bleed Pregnancy, Pregnancy Related, Cesarean Section Complications
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Knee Osteoarthritis, Blood Loss, Pain, Postoperative
Interventions: Tranexamic Acid Pill, Placebo; Drug
Lead sponsor: Campbell Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Germantown, Tennessee

Conditions: Brain Injury Traumatic Mild, Brain Injuries, Brain Injuries, Acute, Head Injury With Intracranial Hemorrhage, Head Injury Trauma, Brain Injury Traumatic Focal With Loss of Consciousness, Skull Fractures, Diffuse Axonal Injury, Intracranial Hemorrhages, Head Injury
Interventions: Validated Questionnaires, Questionnaires, Clinician / Medical Record Variables; Behavioral · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 11 Years to 17 Years
Enrollment: 2,592 participants
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Sacramento, California • Philadelphia, Pennsylvania • Providence, Rhode Island + 3 more

Conditions: Immune Thrombocytopenic Purpura
Interventions: BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV, BMS-986004 1500 mg IV; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more

Conditions: Intracerebral Hemorrhage
Interventions: Not listed
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Avatrombopag, Standard of care; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Watertown, South Dakota

Conditions: Acute Blood Loss Anemia, Osteoarthritis, Hip
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Cesarean Sections
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Obstetrical Complications, Hemorrhage, Labor and Delivery
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 12
States / cities: Birmingham, Alabama • Chicago, Illinois • New York, New York + 9 more

Conditions: Coronary Artery Disease
Interventions: 3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System; Drug · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 2,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 89
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more

Conditions: Osteoarthritis
Interventions: Tranexamic Acid (TXA), ε-Aminocaproic Acid (EACA); Drug
Lead sponsor: Miller Orthopedic Specialists; Other
Eligibility: 18 Years to 90 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Council Bluffs, Iowa

Conditions: Preterm Labor, Preterm Contractions, Abdominal Cramping, Back Pain, Vaginal Pressure, Vaginal Bleeding
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Female only
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Subarachnoid Hemorrhage
Interventions: Pharmacokinetic modeling; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Peripheral Arterial Hemorrhage, Trauma, GI Bleed, Ulcer, Hemorrhage
Interventions: Onyx™ Liquid Embolic System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 22 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Irvine, California • Palo Alto, California + 16 more

Conditions: Heart Failure, Ventricular Dysfunction
Interventions: CoSeal, BioGlue® Surgical Adhesive; Device
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Osteoarthritis, Hip, Joint Deformities, Acquired, Hip Dislocation, Congenital, Osteonecrosis, Arthritis, Rheumatoid
Interventions: Aquamantys, standard electrocautery (Bovie); Device
Lead sponsor: Joint Implant Surgeons, Inc.; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Albany, Ohio

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Orlando, Florida • Iowa City, Iowa • East Lansing, Michigan + 5 more

Conditions: Idiopathic Thrombocytopenic Purpura (ITP)
Interventions: E5501; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Muscular Disorders, Atrophic, Brain Stem Stroke, Spinal Cord Injuries (SCI), Muscular Dystrophies, Muscular Atrophy, Progressive, Pontine Hemorrhage, Pontine Infarction
Interventions: INTENT Neural Interface System; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Immune Thrombocytopenia
Interventions: efgartigimod PH20 SC; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Bentonville, Arkansas • Washington D.C., District of Columbia • Fort Wayne, Indiana + 2 more

Conditions: Bleeding, Clot Blood
Interventions: Aspirin, Warfarin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Houston, Texas

Conditions: Nasotracheal Intubation, Nasal Bleeding
Interventions: Nasotracheal intubation over a bougie, Conventional Nasotracheal Intubation; Procedure
Lead sponsor: University of Iowa; Other
Eligibility: 8 Years to 99 Years
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Intracerebral Hemorrhage
Interventions: PF-05230907; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: St Louis, Missouri • Columbus, Ohio

Search by objective public record fields.

The Effect of Instructed Dental Flossing on Interdental Gingival Bleeding: A Randomized Controlled Clinical Trial

Ideal Time of Oxytocin Infusion During Cesarean Section

Extended Postoperative Oral Tranexamic Acid in Knee Replacement

Screening Emotions in Adolescents at the Hospital for mTBI

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

Delayed Umbilical Cord Clamping - C-section Pilot

Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

EVOLVE Short DAPT Study

Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

Screening To Obviate Preterm Birth

Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage

Onyx™ Liquid Embolic IDE Clinical Study

The Use of CoSeal (Sealant Agent) in Patients During Left Ventricular Assist Device Surgery

Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

Nasotracheal Intubation Over a Bougie

Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage